Partial operating KPIs

This page has 3 company-specific operating KPI charts. A sourced floor is 4. Sector membership does not count.

Boehringer Ingelheim Survodutide: SYNCHRONIZE + LIVERAGE Phase 3 Design

Table: Boehringer Ingelheim Survodutide: SYNCHRONIZE + LIVERAGE Phase 3 Design for Boehringer Ingelheim. 11 rows across Trial / Phase, Indication / Design, Primary Endpoint + Readout Window.
Trial / PhaseIndication / DesignPrimary Endpoint + Readout Window
Phase 1 SAD/MADHealthy volunteers + obesity cohort2017-2019 readouts; demonstrated dose-related pharmacokinetics + initial weight reduction; supported Phase 2 advancement
Phase 2 obesity (46 weeks)Obesity Phase 2bMar 2023 topline: up to ~18.7% mean weight loss at 46 weeks at the 4.8mg weekly high dose vs ~2.0% placebo; GI tolerability comparable to other dual incretins; supports Phase 3 advancement
Phase 2 MASH biopsy (NEJM, 48 weeks)MASH Phase 2b; 293 patients, fibrosis F1-F3NEJM June 7, 2024: dose-related improvement in MASH without worsening of fibrosis across 2.4/4.8/6.0mg, statistically superior to placebo (up to ~83% at the 6.0mg dose vs ~18% placebo); fibrosis improvement up to ~64.5% as a key secondary; supported the LIVERAGE Phase 3 program
SYNCHRONIZE-1 (Phase 3 obesity, registrational)Obesity without T2D; ~725 patientsPrimary endpoint weight loss at 76 weeks; April 2026 topline: up to 16.6% mean weight loss vs 3.2% placebo at 76 weeks; supports EU + FDA filing pathway
SYNCHRONIZE-2 (Phase 3 obesity in type 2 diabetes)Obesity/overweight with type 2 diabetesPhase 3 registrational trial; weight-loss primary endpoint in people with obesity and T2D; parallel pathway alongside SYNCHRONIZE-1
SYNCHRONIZE-CVOT (cardiovascular outcomes)Phase 3 cardiovascular outcomesLong-duration cardiovascular outcomes trial supporting a CV-risk-reduction labeling claim; supports premium positioning vs semaglutide + tirzepatide; long-duration readout
LIVERAGE (Phase 3 MASH, F2-F3)F2-F3 MASH; histology endpointsPhase 3 MASH trial in fibrosis stages F2-F3; MASH resolution + fibrosis improvement at 52 weeks, with long-term outcomes follow-on; competing with Rezdiffra (approved March 2024), semaglutide (MASH approval August 2025), and efruxifermin (Novo/Akero)
LIVERAGE-Cirrhosis (Phase 3 MASH, F4)F4 compensated cirrhosisPhase 3 MASH trial in compensated cirrhosis (fibrosis stage F4); evaluates fibrosis and long-term clinical outcomes in the highest-fibrosis subset
Zealand Pharma partnership economicsRoyalty + milestone obligationsBoehringer pays Zealand royalties on net commercial sales plus development, regulatory, and commercial-launch milestones per the 2011 collaboration; the royalty rate is undisclosed
Boehringer obesity-franchise allocationR&D + capital allocationBoehringer Ingelheim does not disclose Human Pharma R&D at the franchise level; survodutide is its single named obesity + MASH asset. It supports its positioning as the only top-10 Big Pharma without a public listing competing in the GLP-1 space
Editorial. Why survodutide mattersStrategic contextSurvodutide is among the most-advanced glucagon/GLP-1 dual agonists globally and the only Big Pharma asset in this mechanism class. Its Phase 2 obesity result (~18.7% at 46 weeks) and the SYNCHRONIZE-1 Phase 3 result (16.6% at 76 weeks) position Boehringer as a credible #3 Big Pharma incretin franchise behind LLY + NVO. The MASH indication is strategically important: survodutide could give Boehringer both obesity + MASH labels for a single asset

Boehringer Ingelheim Cumulative Payments to Zealand Pharma (Survodutide Partnership)

Line chart: Boehringer Ingelheim Cumulative Payments to Zealand Pharma (Survodutide Partnership) for Boehringer Ingelheim. 2011-2024, values in EUR millions. Cumulative BI payments to Zealand (EUR millions, estimated): 41 in 2011 to 150 in 2024.
Cumulative BI payments to Zealand (EUR millions, estimated)
Boehringer Ingelheim in GLP-1 cover

Boehringer Ingelheim in GLP-1

KPI data tables

Boehringer Ingelheim operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Boehringer Ingelheim R&D Spend: Human Pharma + Animal Health (Annual) (EUR millions)
PeriodHuman Pharma R&D (other therapy areas)Obesity + cardiometabolic (survodutide, est.)Animal Health R&D
20245,350350500
20234,950250600
20224,400180420
20213,500130450
20203,15090460

Source: Boehringer Ingelheim annual reports (boehringer-ingelheim.com; published annually for the prior calendar year); Human Pharma + Animal Health R&D split disclosed in the financial review. Reported group/Human-Pharma R&D: 2024 ~EUR 6.2B group / ~EUR 5.7B Human Pharma; 2023 ~EUR 5.8B / ~EUR 5.2B; 2022 ~EUR 5.0B group. The Human-Pharma + Animal-Health totals match reported figures; the obesity/cardiometabolic sub-allocation is estimate-driven because BI does not disclose therapy-area-level R&D budgets.

Boehringer Ingelheim Cumulative Payments to Zealand Pharma (Survodutide Partnership) (EUR millions)
PeriodCumulative BI payments to Zealand (EUR millions, estimated)
2024150
2023140
2022110
202095
201555
201141

Source: Zealand Pharma annual + interim reports (counterparty disclosure of payments received from the Boehringer partnership); original 2011 partnership announcement (lead candidate ZP2929); disclosed milestone receipts (~EUR 20M in 2020, ~EUR 30M in 2023). The cumulative curve is estimate-driven and anchored to these disclosed milestones (Zealand aggregates partner revenue rather than itemizing a BI-specific cumulative figure), so intermediate-year values are approximate.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Boehringer Ingelheim - KPIs | Sterling